United States – March 31, 2023 —

RecordZap.com is an innovative legal services business that is revolutionizing the way individuals with criminal records expunge, seal, or clear their records. This cutting-edge platform simplifies and streamlines the expungement process using technology, making it easier for individuals to clear their records and move forward with their lives.

According to the National Institute of Justice, approximately one-third of adults in the United States have a criminal record. This translates to around 70 million Americans who face significant challenges in securing employment, housing, and education opportunities, as well as voting rights. However, many Americans with criminal records are not aware that they can get their records cleared, sealed, or expunged.

Here are a few statistics that shed light on the scope of these challenges:

• Employment: According to a report by the National Employment Law Project, up to 1 in 3 American adults have some type of criminal record that may show up on a background check. Individuals with criminal records are often denied employment opportunities, with some estimates suggesting that they are 50% less likely to receive a job offer than similarly qualified applicants without a criminal record.

• Housing: Individuals with criminal records may also face difficulties obtaining housing, particularly if they have been convicted of a drug offense or a crime related to violence. According to a report by the National Low Income Housing Coalition, more than 2,000 public housing authorities have policies that restrict access to housing based on criminal records.

• Education: Students with criminal records may also face difficulties accessing education. According to a report by The Sentencing Project, more than two-thirds of colleges and universities collect information about applicants’ criminal histories, and more than a quarter of those institutions use that information to deny admission to some applicants.

• Voting: In some states, individuals with criminal records may be denied the right to vote. According to the Sentencing Project, an estimated 6.1 million Americans are unable to vote due to felony disenfranchisement laws.

Many Americans with criminal records for non-violent crimes, including traffic violations charged as misdemeanors, have no idea that they can get their records cleared. But, doing so can be very difficult and confusing by non-attorneys.

RecordZap.com was founded by a team of legal professionals who were frustrated with how difficult and confusing the expungement process could be. The platform allows individuals to easily check their eligibility for expungement, connect with experienced attorneys, and complete the process with ease.

Having a criminal record can also place stigma on individuals and affect their social relationships, for instance with forming new relationships when individuals with criminal records are simply Googled by new friends or romantic partners. 

Further, demographic factors such as race, gender, and socioeconomic status can play a role in difficulties Americans with criminal records face. Record Zap can help clear, seal, or expunge misdemeanor and felony criminal records in multiple states.

RecordZap.com is committed to providing comprehensive support to individuals looking to clear their criminal records. This includes resources and support for ensuring inaccurate negative information about them that remains online gets removed.

By simplifying the expungement process and providing comprehensive support, RecordZap.com is giving individuals the chance to start fresh and build a better future.

For more information please visit www.recordzap.com.

Disclaimer: This article does not provide legal advice.

Contact Info:
Name: Sam Field
Email: Send Email
Organization: RecordZap
Address: United States
Website: https://www.recordzap.com

Release ID: 89093133

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

The Molecular Interaction division is proud to announce the launch of its BioID platform for proximity-dependent biotin identification. This latest platform offers a highly sophisticated and innovative tool for investigating protein-protein interactions and identifying the specific targets of a protein in complex cellular environments.

New York, United States – March 30, 2023 /MarketersMEDIA/ —

Molecular Interaction is a subdivision of Creative Proteomics that focuses on the study of biomolecular interactions. The project manager of the division is proud to announce the launch of its BioID platform for proximity-dependent biotin identification. This latest platform offers a highly sophisticated and innovative tool for investigating protein-protein interactions and identifying the specific targets of a protein in complex cellular environments.

The BioID platform is based on a proximity-dependent labeling technique that uses a promiscuous biotin ligase enzyme to attach biotin to proteins in close proximity. The biotinylated proteins can then be isolated and identified using mass spectrometry-based protein analysis, providing insights into the proteins and pathways involved in various biological processes.

“Protein-protein interactions are essential for many cellular processes, and understanding these interactions is critical for advancing our understanding of disease mechanisms and developing new therapies,” said the senior scientist at Creative Proteomics. “The BioID platform provides a powerful tool for investigating these interactions in a high-throughput and unbiased manner.”

One of the key advantages of the BioID platform is its ability to identify proteins that interact with a target protein within the complex environment of the cell. This is achieved by expressing a fusion protein consisting of the target protein and the biotin ligase enzyme in the cell, which results in the biotinylation of proteins in close proximity to the target protein. The labeled proteins can then be captured and identified using mass spectrometry-based protein analysis.

Creative Proteomics offers a range of services based on the BioID platform, including target identification, validation, and characterization. The platform can be used for a variety of applications, including drug discovery, protein engineering, and biomarker discovery.

“We are excited to offer the BioID platform to our clients, and we believe that it will be a valuable addition to our portfolio of proteomics services. Our team of highly skilled and experienced scientists is dedicated to providing the highest quality services to our clients, and we are committed to helping them achieve their research goals,” he further added.

The launch of the BioID platform represents a significant step forward in the field of proteomics, providing researchers with a powerful tool for investigating protein-protein interactions and identifying specific protein targets within complex cellular environments. With its expertise and capabilities in the field of proteomics, Creative Proteomics is well-positioned to provide high-quality services to researchers in the academic, pharmaceutical, and biotechnology industries.

About Creative Proteomics

Creative Proteomics, a seasoned provider of proteomics, metabolomics, and bioinformatics services, is well-equipped with new and advanced technologies to meet the increasing needs of scientists in proteome and metabolism research.

Contact Info:
Name: Dora West
Email: Send Email
Organization: Creative Proteomics
Website: https://www.iaanalysis.com/

Release ID: 89093076

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

Creative Proteomics Lipidomics today announced the launch of its Phospholipid Fatty Acids (PLFA) Analysis Service, which is designed to provide an efficient and cost-effective way for researchers to analyze the microbial community structure in various environments.

New York, United States – March 30, 2023 /MarketersMEDIA/ —

Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomic research services for biomedical institutions as well as biotechnological and pharmaceutical companies. The company today announced the launch of its Phospholipid Fatty Acids (PLFA) Analysis Service, which is designed to provide an efficient and cost-effective way for researchers to analyze the microbial community structure in various environments.

Phospholipid fatty acids are a group of biomolecules that are found in the cell membranes of all living organisms, including bacteria, fungi, and plants. The composition of these fatty acids can provide valuable information about the diversity and abundance of microbial communities in a given environment. PLFA analysis has become a popular method for characterizing microbial communities in soil, water, and other environmental samples.

“We are excited to add the PLFA analysis service to our portfolio of environmental microbiology services,” said the Chief Scientist at Creative Proteomics. “This PLFA service will allow us to help our customers better understand the structure and function of microbial communities in their environmental samples.”

The PLFA analysis service at Creative Proteomics uses gas chromatography-mass spectrometry (GC-MS) to identify and quantify the individual fatty acids present in the phospholipid fraction of microbial cell membranes. The service provides detailed information on the total biomass and the composition of different groups of microorganisms, such as gram-positive and gram-negative bacteria, fungi, and actinomycetes.

The PLFA analysis service is expected to be particularly useful in environmental microbiology research, where understanding the structure and function of microbial communities is essential to studying the impact of human activities on the environment. The service can also be used in other fields, such as food microbiology and medical microbiology, where microbial community analysis is becoming increasingly important.

“Our service is designed to be flexible and customizable to meet the specific needs of each customer. We offer a range of sample preparation and extraction methods, and can provide customized data analysis and reporting to ensure that our customers get the most out of their PLFA data. We believe that our PLFA analysis service will be a valuable tool for researchers in a wide range of fields,” he further added.

About Creative Proteomics

Creative Proteomics has gradually grown into an integrated service provider with both targeted lipidomics and untargeted lipidomics analysis services for researchers in the pharmaceutical, biotechnology, agriculture, and nutrition industries, as well as academic and government organizations. 

Contact Info:
Name: Dora West
Email: Send Email
Organization: Creative Proteomics
Website: https://lipidomics.creative-proteomics.com/

Release ID: 89093075

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

CD Genomics MicrobioSeq is pleased to announce the launch of its Microbial Biomarker Discovery Service, a revolutionary solution that promises to transform microbiology research.

New York, United States – March 30, 2023 /MarketersMEDIA/ —

MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research.

Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role that microbial communities play in maintaining human health. However, analyzing the vast amounts of data generated by high-throughput sequencing of microbiome samples can be a daunting task. CD Genomics’ Microbial Biomarker Discovery service simplifies this process by providing a comprehensive solution that includes sample collection, sequencing, data analysis, and biomarker identification.

The Microbial Biomarker Discovery service uses CD Genomics’ proprietary MicrobioSeq platform, which combines next-generation sequencing with advanced bioinformatics tools. This platform has been optimized to analyze complex microbiome samples, including those from human, animal, plant, and environmental sources. By identifying microbial biomarkers that are associated with specific diseases or conditions, the service can provide valuable insights into the underlying biological mechanisms of these diseases.

With its advanced technology platform and cutting-edge sequencing and analysis algorithms, this service is designed to accurately and efficiently identify biomarkers that can be used to diagnose or predict the onset of a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. With its ability to identify microbial biomarkers that are associated with specific diseases, this service has the potential to accelerate the development of new drugs and diagnostics that can improve human health.

“CD Genomics is committed to providing innovative solutions that help researchers advance their understanding of the microbiome and its role in human health,” said a spokesperson for CD Genomics. “Our Microbial Biomarker Discovery service is the latest example of our commitment to developing cutting-edge technologies that can improve the lives of people around the world.”

In the increasingly competitive biotech industry, Microbioseq’s Microbial Biomarker Discovery solution sets the company apart as a leader in microbiology research. By providing researchers with the tools they need to advance their work, CD Genomics is supporting the growth and development of the industry as a whole.

About the MicrobioSeq Division of CD Genomics

MicrobioSeq is the microbial genomics division of CD Genomics, a genomics service company with a renowned reputation for providing reliable microbial products, microbial testing services, microbial genomics services, and integrated bioinformatics services.

Contact Info:
Name: Kiko Garcia
Email: Send Email
Organization: CD Genomics
Website: https://www.cd-genomics.com/microbioseq/

Release ID: 89093066

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

CD Genomics has recently launched TCR-seq, a powerful service that enables rapid and efficient analysis of T-cell receptor (TCR) diversity and clonality, providing critical support for immune and cancer research.

New York, United States – March 30, 2023 /MarketersMEDIA/ —

CD Genomics is a world-leading genomics services company that continues to innovate in high throughput sequencing services for the genomics industry, as well as genotyping, bioinformatics, microarrays, and more. The company has recently launched TCR-seq, a powerful service that enables rapid and efficient analysis of T-cell receptor (TCR) diversity and clonality, providing critical support for immune and cancer research.

As immunotherapy gains widespread use, increasing attention is being focused on T-cell clone diversity and clonality, which is crucial for evaluating the effectiveness and safety of immunotherapy. TCR-Seq is a state-of-the-art high-throughput sequencing technology that comprehensively analyzes T-cell clones. CD Genomics’ TCR-Seq service can be applied to various sample types, including blood, tissue, and cells, to obtain high-quality TCR sequences that enable researchers to gain a comprehensive understanding of T-cell clone diversity and clonality.

The TCR-Seq service provides several advantages：

First, CD Genomics efficiently extracts DNA or RNA and uses the Illumina platform for high-throughput sequencing, ensuring the quality and reliability of the data.

Second, CD Genomics utilizes multiple bioinformatics tools, including VDJtools and tcR, to accurately genotype TCR sequences and identify clones.

Finally, CD Genomics provides detailed analysis reports that help researchers gain an in-depth understanding of T-cell clone diversity and clonality in the samples.

“Our TCR-Seq service enables researchers to gain a better understanding of T-cell clone diversity and clonality, providing critical support for immunotherapy research and development,” said a senior scientist at CD Genomics. “Our service delivers rapid and efficient analysis of T-cell receptors, providing researchers with accurate and reliable data that drives further development in immune and cancer research.”

The TCR-Seq service has a broad range of applications and can be used in research and development of immunotherapy drugs, cancer immunology, viral infection research, and other areas. CD Genomics also offers a suite of other genetic sequencing services, including RNA-Seq, WGS, WES, and more, providing comprehensive genetic sequencing solutions for researchers.

Moreover, the solution used has high sensitivity and specificity, detecting even tiny amounts of TCR in low-concentration samples and detecting all TCR, allowing researchers to obtain more comprehensive and accurate information, providing a better understanding of the immune system’s mechanism. CD Genomics’ TCR sequencing solution is a high-quality, reliable, and comprehensive analysis method, providing researchers with a more in-depth and accurate analysis of the immune system.

About CD Genomics

CD Genomics is a genomics service provider well-known for providing reliable sequencing and bioinformatics analysis services, covering the delivery of high-quality next-generation sequencing, long read sequencing, and microarray services for the research community.

Contact Info:
Name: Kiko Garcia
Email: Send Email
Organization: CD Genomics
Website: https://www.cd-genomics.com/

Release ID: 89093069

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

SetSchedule is a technology company based in Irvine California that focuses on information SaaS products including business development and office automation.

Irvine, California – March 30, 2023 —

SetSchedule is a technology company based in Irvine California that focuses on information SaaS products including business development and office automation. On March 16th SetSchedule announced its successful acquisition of Rentastic, an accounting solution catering specifically to real estate investors.

With its second acquisition this year, the tech company intends to leverage AI and machine learning to provide a comprehensive suite of professional tools and resources to verticals in the real estate industry. SetSchedule, with this move, is well-positioned to become the go-to destination for real estate investors who want to gain clear transparency around their portfolios, property return on investments, and expense ratios.

Rentastic, an alternative accounting solution for real estate investors, offers a comprehensive suite of investor features to track income and expenses for a real estate investor’s portfolio. Its advanced software empowers real estate investors with tools to monitor lease payments, manage income and expenses, and perform deal analysis, all in one place. It allows investors and accountants to simplify their real estate investment operations and make data-driven decisions.

“I’ve checked it out for a while, and when I think about the synergy between SetSchedule’s and Rentastic’s potential clients, it totally gets me pumped to bring Rentastic into our tech stack,” said Roy Dekel, SetSchedule’s CEO. “While there’s so much more to come, this acquisition further cements our position as the leading technology firm in the real estate sector.”

SetSchedule will bring in the talented Rentastic team on board, who will work closely with them to develop new features and improve the overall user experience.

This acquisition marks a significant milestone in the company’s growth strategy and its commitment to delivering the most advanced and comprehensive real estate technology solutions on the market.

About SetSchedule

SetSchedule is an American technology company that disrupts the real estate industry by leveraging SaaS and consumer cloud communication products, artificial intelligence, and autonomous business flow applications to eliminate the struggle behind establishing a connection.

SetSchedule’s goal is to innovate multiple industries with cutting-edge tools that allow solopreneurs and midsized businesses to grow their business, faster, more economically, and manage their offices better.

About Rentastic

Rentastic was founded in 2020 for real estate investors. Offering a suite of real estate investor features, Rentastic provides tools to help track, report, and grow an investor’s portfolio of properties.

For more information about SetSchedule, visit setschedule.com. For more information about Rentastic, visit rentastic.io.

Contact Info:
Name: Stanley Bawalan
Email: Send Email
Organization: SetSchedule
Website: https://www.setschedule.com/

Release ID: 89093079

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

Barker Associates is moving to an employee ownership model. The transition will preserve the culture of the business and provide a stake in the company for each and every employee.

Braintree, Essex – March 30, 2023 —

Barker Associates, the leading multi-disciplinary property and energy consultancy, has today announced it will be transitioning to an employee-owned business model with immediate effect, following the sale of its shares to the company’s employees.

During its 36-year history, Barker has built an enviable reputation for delivering top-quality surveying and architectural services to customers across the UK, particularly within the education sector and the transition to an employee-owned business is a significant milestone for the company. Under the new ownership structure, each of Barker’s employees will have a stake in the business and be empowered to make decisions that will benefit the company and themselves. 

This transition will also ensure the company’s existing culture will be preserved and continued for future generations and the business continues to grow as employees are motivated to work towards the success of the business.

Barker’s current leadership team is excited about the change and is committed to ensuring a smooth and successful transition. 

Managing Partner, Stuart White said: 

“Moving to an employee-owned business model is a natural evolution for Barker. We believe that giving our employees a stake in the company is the best way to ensure that we continue to deliver innovative solutions and superior service to our clients. We also recognise employee ownership will foster a culture of collaboration and shared responsibility that will drive innovation and growth for years to come.” 

He added: 

“We’re thrilled to embark on this new chapter in our company’s history, and we look forward to working with our employees to build a stronger, more sustainable business.” 

Barker is committed to transparency and open communication with its employees and key stakeholders throughout the transition process. The company will be hosting a series of informational sessions to ensure that everyone is informed and engaged in the process. 

About Barker Associates 

Barker Associates has been delivering exceptional results for their clients for more than 30 years. As integrated property consultants, the team behind the company has specialist industry knowledge that is unrivaled by other businesses operating on the market. The company also works to ensure that their services are both seamless and stress-free. 

The business aims to provide innovative solutions from concept to building work and beyond. The team constantly works to improve outcomes and ensure that they are always delivering the absolute best levels of client services and support. The new company structure will ensure that each team member and employee is even more motivated to deliver a high standard of service to every client as they will personally benefit from the continued success of the brand. 

More information about Barker Associates can be found on the business website. Alternatively, a representative for the company can be contacted directly using the information provided below. 

Contact Info:
Name: Noor Shameel
Email: Send Email
Organization: Barker Associates
Address: Majesty House, Avenue West, Skyline 120, Braintree, Essex, CM77 7AA
Phone: 01279 647 111
Website: https://www.barker-associates.co.uk/

Release ID: 89093121

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

CD Genomics has announced the launch of its advanced Mitochondrial Diseases Panel Sequencing services. This new panel enables rapid and accurate detection of mutations in mitochondrial DNA (mtDNA) that are associated with a wide range of mitochondrial disorders.

New York, United States – March 30, 2023 /MarketersMEDIA/ —

CD Genomics, a leading biotechnology company specializing in genomics and sequencing, has announced the launch of its advanced Mitochondrial Diseases Panel Sequencing services. This new panel enables rapid and accurate detection of mutations in mitochondrial DNA (mtDNA) that are associated with a wide range of mitochondrial disorders.

Mitochondrial diseases are a complex and heterogeneous group of disorders caused by mutations in mitochondrial DNA (mtDNA) or nuclear genes that encode proteins involved in mitochondrial function. The symptoms of these disorders can vary widely and may include muscle weakness, neurodegenerative disorders, vision and hearing loss, and metabolic disorders. However, detecting mitochondrial diseases can be challenging, as the symptoms are often nonspecific and can overlap with those of other conditions.

To address this challenge, CD Genomics has developed a comprehensive Mitochondrial Diseases Panel Sequencing service that enables researchers to accurately identify mitochondrial DNA and nuclear DNA mutations and obtain a comprehensive view of the patient’s genetic makeup. The panel includes over 200 genes associated with mitochondrial function and metabolism, covering both mtDNA and nuclear DNA mutations.

The Mitochondrial Diseases Panel Sequencing service is validated for high accuracy, sensitivity, and specificity, ensuring reliable results. The analysis is performed using state-of-the-art sequencing technologies, including Illumina PE150 and Illumina MiSeq, and is supported by CD Genomics’ team of experienced scientists and bioinformaticians.

“We are excited to launch our comprehensive Mitochondrial Diseases Panel Sequencing service for research use only, which provides a powerful tool for researchers to identify genetic mutations associated with mitochondrial diseases,” said the chief scientist at CD Genomics. “Our panel includes a broad range of genes related to mitochondrial function and metabolism, enabling researchers to obtain a comprehensive view of the patient’s genetic makeup and develop new insights into the underlying genetic causes of these diseases.”

In addition to the standard panel, CD Genomics also offers custom Mitochondrial Diseases Panel Sequencing, allowing researchers to tailor the panel to their specific research needs. Customers can choose from a variety of options, including specific genes or regions of interest, sample types, and coverage depth.

CD Genomics is committed to providing high-quality genomics services to researchers worldwide. With the launch of its comprehensive Mitochondrial Diseases Panel Sequencing service for research use only, the company is poised to make a significant contribution to the understanding of mitochondrial diseases.

About CD Genomics

CD Genomics offers predesigned NGS panels, which include a designed library of targeted sequencings well as a custom panel that allows customers to select genes of interest and customize individual sequencing panels. 

Contact Info:
Name: Kiko Garcia
Email: Send Email
Organization: CD Genomics
Website: https://www.cd-genomics.com/diseasepanel/

Release ID: 89093072

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

The new collection is a limited edition and it includes high-quality t-shirts that are perfect for the spring season

United States – March 30, 2023 /MarketersMEDIA/ —

IF… THEN WELL is excited to announce the launch of its Spring 2023 color collection on March 30th, 2023. The brand’s latest collection features seasonal colors that are perfect for the upcoming spring season and inspired by the vibrant nature of the season. IF… THEN WELL manufactures its t-shirts from Pima cotton sourced directly from Peru, where the premium fabric has its earliest traced roots. Known for its natural softness and cooling properties, Peruvian Pima cotton is considered one of the world’s finest and most luxurious cotton varieties in the world.

Based in Miami, Florida, IF… THEN WELL has limited marketing and low overhead costs, and by selling directly to consumers via their website, they eliminate middlemen, resulting in cost savings that are passed on to their customers. IF…. THEN WELL’s approach allows them to provide high-end quality at mid-range pricing, making their t-shirts an accessible luxury for any discerning consumer.

Designed with versatility in mind, IF… THEN WELL’s Spring 2023 collection is tailored to be worn untucked and look just as good paired down with shorts or dressed up under a blazer. The collection is available individually or as part of a specially priced Men’s T-Shirt Bundle, making it easy to mix and match the perfect color combinations to suit any style.

“The 2023 Spring collection embodies our men’s fashion ideal,” said Aldo Savignano, co-founder of IF… THEN WELL. “Clothing that gets noticed without looking like it’s trying to get noticed. It’s all about timeless, effortless style that remains uncompromising in quality and comfort.”

IF…. THEN WELL’s Spring 2023 T-Shirt collection is available for purchase exclusively on their website on March 30th, 2023. As with all limited edition products, customers are encouraged to act fast to secure their preferred colors as they may not be restocked once sold out. The collection has been designed with both comfort and style in mind as the brand prides itself on creating t-shirts that not only look great but also feel great to wear.

For more information about IF… THEN WELL Men’s Premium T-Shirt brand and to shop their Spring 2023 collection, visit their website at www.ifthenwell.com.

Contact Info:
Name: Aldo Savignano
Email: Send Email
Organization: IF… THEN WELL
Phone: 305-414-1324
Website: https://ifthenwell.com/

Release ID: 89093067

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

iDenfy will enhance Duobus’ pre-employment screening process with its full-stack identity verification solution

Kaunas, Kaunas County, Lithuania – March 30, 2023 /MarketersMEDIA/ —

iDenfy, a global RegTech startup offering ID verification and fraud prevention tools, announced a new partnership with Duobus, a  Dutch healthcare platform designed for both organizations and self-employed healthcare professionals. iDenfy will be in charge of conducting secure identity verification checks and facilitating the onboarding process for Duobus.

With the growing number of people using healthcare applications, there has been a corresponding increase in associated fraud risks. To address these security challenges, according to iDenfy, AI-powered identity verification measures have become crucial in the fintech industry and healthcare. 

Duobus supports this technological approach and acknowledges that fraud and identity theft has become more prevalent in recent years, particularly with the global pandemic. To combat security threats and ensure that only authorized individuals gain access to its platform, the company started looking for robust remote verification measures and partnered with iDenfy. 

Patients expect a hassle-free experience when finding the right healthcare specialist online. Duobus aims to extend the same level of exceptional service to its healthcare professionals. That’s why for self-employed specialists, the company provides a user-friendly platform, offering features like automated invoicing and online training programs to enhance their skills in healthcare. 

As claimed by Duobus, its platform offers more than just a user-friendly interface. Before an individual can start working for an organization through Duobus, regardless of whether they are a Duobus employee or a self-employed healthcare professional, they must complete the mandatory verification process. This process involves scrutinizing relevant documents, verifying the individual’s identity, and determining their eligibility to work in the Netherlands. 

Duobus has partnered with iDenfy to enable automated Know Your Customer (KYC) compliance and reduce authentication time. The company currently uses a fully automated identity verification solution provided by iDenfy, to ensure swift and secure KYC checks for its staff members and specialists. Duobus claims that this partnership allows the company to adopt a technology-first approach and reduce the need for manual processes in the healthcare business.

iDenfy’s AI-powered ID verification process involves four steps: selecting the country and type of document, capturing a photo of the ID document, and taking a selfie. As a result, the onboarding process for Duobus users now takes just a few minutes. By adopting iDenfy’s software, the healthcare platform has optimized customer onboarding time while maintaining high levels of security and a positive user experience.

The KYC startup utilizes 3D liveness technology for its biometric ID verification solution, generating a facial map of the user that can be utilized to blacklist customers or identify duplicates. Its facial recognition system can detect masks, deepfakes, and other fraudulent attempts during the verification process, allowing Duobus to minimize its fraud rate. 

Denfy is certified to meet the ISO/IEC 27001 standard, which guarantees that Duobus users’ data is handled with the highest level of security protocols in place. According to iDenfy, with this partnership, its team will aim to help Duobus scale without compromising compliance and identity verification needs. 

“Making digital healthcare more accessible begins with greater transparency. We’re thrilled to partner with Duobus. Our identity verification solution will ensure a seamless sign-up process while providing the necessary level of confidence.” — commented Domantas Ciulde, the CEO of iDenfy. 

About Us: About iDenfy

iDenfy is a RegTech startup that provides AML, KYC, and KYB compliance solutions to businesses of all sizes. The company has been recognized as a leading identity verification software in G2’s Winter 2023 report. iDenfy has also won the “Enabler of the Year” category at the Lithuanian Fintech 2023 awards.

For more information and business inquiries, please visit www.idenfy.com.

Contact Info:
Name: Eva Azaraviciute
Email: Send Email
Organization: iDenfy
Address: Barsausko g. 59
Phone: +37063815442
Website: https://www.idenfy.com/

Release ID: 89093065

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.